| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,383,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.53 - $28.72 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 2 |
| Insider 6 Months : 2 |
| Insider 3/6 Months : 4.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53 |
53 |
53 |
53 |
| Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
101,351 |
146,351 |
179,848 |
214,693 |
| Total Sell Value |
$2,152,463 |
$3,094,133 |
$3,971,419 |
$5,040,525 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
11 |
12 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2021-03-01 |
4 |
OE |
$11.05 |
$166,468 |
D/D |
15,065 |
101,285 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2020-12-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,000 |
0 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2020-12-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
86,220 |
|
- |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• – – |
2020-12-17 |
4 |
S |
$43.85 |
$165,621 |
D/D |
(3,777) |
28,395 |
|
-0% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2020-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
88,220 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2020-06-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
88,602 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2020-06-12 |
4 |
OE |
$11.05 |
$110,500 |
D/D |
10,000 |
90,602 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-04-06 |
4 |
S |
$27.10 |
$17,685,509 |
I/I |
(644,771) |
606,005 |
|
-4% |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-03-20 |
4 |
S |
$29.89 |
$1,517,642 |
D/D |
(50,770) |
5,012,430 |
|
-13% |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-03-19 |
4 |
S |
$28.23 |
$756,593 |
D/D |
(26,800) |
5,063,200 |
|
-9% |
|
| Dahiyat Bassil I |
President and CEO |
• • – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,605 |
143,504 |
|
- |
|
| Eckert Celia |
VP, General Counsel and Secy |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,147 |
3,147 |
|
- |
|
| Desjarlais John R |
Sr. V.P., Research & CSO |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,085 |
92,953 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,777 |
80,422 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-01-08 |
4 |
S |
$36.68 |
$2,232,932 |
I/I |
(60,876) |
1,250,776 |
|
12% |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-01-07 |
4 |
S |
$35.95 |
$217,390 |
I/I |
(6,047) |
1,311,652 |
|
11% |
|
| Stafford John S Iii |
10% Owner |
– – • |
2020-01-06 |
4 |
S |
$35.81 |
$2,107,907 |
I/I |
(58,862) |
1,317,699 |
|
11% |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-26 |
4 |
S |
$40.04 |
$164,925 |
I/I |
(4,119) |
1,376,561 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-24 |
4 |
S |
$39.71 |
$1,736,121 |
I/I |
(43,720) |
1,380,680 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-23 |
4 |
S |
$39.51 |
$3,622,342 |
I/I |
(91,677) |
1,424,400 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-20 |
4 |
S |
$39.39 |
$2,892,132 |
I/I |
(73,423) |
1,516,077 |
|
- |
|
| Yang Allen |
SVP, Chief Medical Officer |
• – – |
2019-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
31,900 |
31,900 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2019-12-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
73,645 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-11 |
4 |
S |
$38.68 |
$1,467,945 |
I/I |
(37,951) |
1,589,500 |
|
- |
|
| Stafford John S Iii |
10% Owner |
– – • |
2019-12-10 |
4 |
S |
$40.13 |
$10,121,789 |
I/I |
(252,225) |
1,627,451 |
|
- |
|
312 Records found
|
|
Page 4 of 13 |
|
|
0.75 (3.9%) 
